Anupma Nayak, MD
Pathology and Laboratory Medicine
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP
Headshot of Anupma Nayak, MD
Penn Medicine Provider

About me

  • Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania

My areas of clinical expertise:

Breast Pathology

Genitourinary Pathology

Education and training

  • Medical School: King George's Medical University
  • Residency: All India Institute of Medical Sciences
  • Residency: Long Island Jewish Medical Center
  • Residency: Texas Medical Center
  • Fellowship: All India Institute of Medical Sciences

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Nayak is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

DeMichele A, Clark A, Shea E, Bayne L, Sterner C, Rohn K, Eberle-Dwyer S, Pan T-C, Nivar I, Chen Y, Wileyto EP, Berry L, DeLuca S, Savage J, Makhlin I, Pant D, Egunsola A, Mears N, Goodspeed B, Chislock E, Graves J, Wang J, Shih N, Belka G, Berry D, Nayak A, Feldman M, Martin H, Chodosh L. Targeting Dormant Tumor Cells to Prevent Recurrent Breast Cancer: a randomized phase 2 trial. , Nature Medicine: 2025


Griffin B. Spychalski1, Andrew A. Lin, Stephanie J. Yang, Hanfei Shen, Jean Rosario, Kyle Tien, Kate French, Miriyam Ghali, Stephanie Yee, Melinda Yin, Michael D. Feldman, Emily F. Conant, Susan P. Weinstein, Erica L. Carpenter, David Issadore, Anupma Nayak miRNA Panel from HER2+ and CD24+ Plasma Extracellular Vesicle Subpopulations as Biomarkers of Early-stage Breast Cancer , Breast Cancer Res., 27(1): 2025,90


Narasimhamurthy M, Le A, Boruah N, Moses R, Kelly G, Bleiweiss I, Maxwell KN, Nayak A. Clinicopathologic Features of Breast Tumors in Germline TP53 Variant-Associated Li-Fraumeni Syndrome. , Am J Surg Pathol., 49(3): 2025,195-205


Kaitlin Demarest, Arravinth Anantharajah, Kara N. Maxwell1, Mersedeh Rohanizadegan, Angela Bradbury, Katherine L Nathanson, Susan Domchek, Anupma Nayak, Payal D. Shah Pathogenic Germline Variants in Patients with Metaplastic Breast Cancer , JAMA Network Open , 8(2): 2025


Young AJ, Pantel AR, Kiani M, Doot RK, Bagheri S, Pryma DA, Farwell MD, Li S, Lee H, Schubert EK, Secreto A, Zuckerman SP, Nayak A, Choi H, Carlin S, DeMichele A, Mankoff DA, Zhou R, Mach RH, McDonald ES. Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted 18F-Fluorthanatrace PET in Breast Cancer. , J Nucl Med. , 65((12)): 2024,1862-68


Tchou J, Gottipati S, Goldbach M, Baxter M, Venters S, Chen Y, Gonzalves D, Ahmad Z, Nayak A, Mukhtar R, Boughey J. Change in Biomarker Profile after neoadjuvant chemotherapy is prognostic and is especially common in patients with HER2+ breast cancer. , Ann Surg Oncol., 31(12): 2024,8093-8101


Li X, Nguyen TTA, Zhang J, Nayak A, Liu Y, Duckworth LA, Zhang G, Bakkar R, Agarwal I, Hou Y, Guo H, Huang X, Wei S, Yasmeen S, Thaer K, Huang H, Zhang H, Smith GH, Turashvili G, Peng L, Liu Y, Yang W, Siziopikou KP. Validation Study of the Newly Proposed Refined Diagnostic Criteria for Malignant Phyllodes Tumor With 136 Borderline and Malignant Phyllodes Tumor Cases , Am J Surg Pathol., 48(9): 2024,1146-1153


Ito K, Harada I, Martinez C, Sato K, Lee E, Port E, Byerly JH, Nayak A, Tripathi E, Zhu J, Irie HY. MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases. , Cancer Res Commun., 28(4): 2024,946-957


Wineland D, Le AN, Hausler R, Kelly G, Barrett E, Desai H, Wubbenhorst B, Pluta J, Bastian P, Symecko H, D'Andrea K, Doucette A, Gabriel P, Reiss KA, Nayak A, Feldman M, Domchek SM, Nathanson KL, Maxwell KN; Regeneron Genetics Center; Penn Medicine Biobank. Biallelic BRCA loss and homologous recombination deficiency in non-breast/ovarian tumors in germline BRCA1/2 carriers , JCO Precis Oncol.: 2023,e2300036


Thacker G, Henry S, Nandi A, Debnath R, Singh S, Nayak A, Susnik B, Boone MM, Zhang Q, Kesmodel SB, Gumber S, Das GM, Kambayashi T, Dos Santos CO, Chakrabarti R. Immature natural killer cells promote progression of triple-negative breast cancer. , Sci Transl Med., 15(686): 2023,eabl4414


View all publications